Regeneron Pharmaceuticals/ US75886F1075 /
| 2024-04-18 9:59:58 PM | Chg. -7.49 | Volume | Bid- | Ask- | Market Capitalization | Dividend Y. | P/E Ratio |
|---|---|---|---|---|---|---|---|
| 893.66USD | -0.83% | 25,275 Turnover: 22.67 mill. |
-Bid Size: - | -Ask Size: - | 98.13 bill.USD | - | 24.13 |
Assets
| 2016 US GAAP in mill. USD |
2017 US GAAP in mill. USD |
2018 US GAAP in mill. USD |
2019 US GAAP in mill. USD |
2020 US GAAP in mill. USD |
|||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Property and Equipment | 2,083.4210 | 2,358.6050 | 2,575.8000 | 2,890.4000 | 3,221.6000 | ||||||
| Intangible Assets | - | - | - | - | - | ||||||
| Long-Term Investments | 864.2600 | 1,486.4940 | 1,755 | 3,256.8000 | 3,135.6000 | ||||||
| Fixed Assets | 3,793.2780 | 4,429.2560 | 5,286.9000 | 7,116.1000 | 7,384.2000 | ||||||
| Inventories | 399.3560 | 726.1380 | 1,151.2000 | 1,415.5000 | 1,916.6000 | ||||||
| Accounts Receivable | 1,343.3680 | 1,538.6420 | 1,723.7000 | 2,100 | 3,111.5000 | ||||||
| Cash and Cash Equivalents | 535.2030 | 812.7330 | 1,467.7000 | 1,617.8000 | 2,193.7000 | ||||||
| Current Assets | 3,180.1880 | 4,335.0300 | 6,447.6000 | 7,689.1000 | 9,779.1000 | ||||||
| Total Assets | 6,973.4660 | 8,764.2860 | 11,734.5000 | 14,805.2000 | 17,163.3000 | ||||||
Liabilities
| 2016 US GAAP in mill. USD |
2017 US GAAP in mill. USD |
2018 US GAAP in mill. USD |
2019 US GAAP in mill. USD |
2020 US GAAP in mill. USD |
|||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Accounts Payable | - | - | 218.2000 | 418.1000 | 475.5000 | ||||||
| Long-term debt | 351.5690 | 703.4530 | 708.5000 | 713.9000 | 2,695.7000 | ||||||
| Liabilities to Banks | - | - | - | - | - | ||||||
| Provisions | - | - | - | - | - | ||||||
| Liabilities | 2,524.2210 | 2,620.2080 | 2,977.2000 | 3,715.5000 | 6,138 | ||||||
| Share Capital | .1080 | .1100 | .1000 | .1000 | .1000 | ||||||
| Total Equity | 4,449.2450 | 6,144.0780 | 8,757.3000 | 11,089.7000 | 11,025.3000 | ||||||
| Minority Interests | - | - | - | - | - | ||||||
| Total liabilities equity | 6,973.4660 | 8,764.2860 | 11,734.5000 | 14,805.2000 | 17,163.3000 | ||||||
Income Statement
| 2016 US GAAP in mill. USD |
2017 US GAAP in mill. USD |
2018 US GAAP in mill. USD |
2019 US GAAP in mill. USD |
2020 US GAAP in mill. USD |
|||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenues | 4,860.4270 | 5,872.2270 | 6,710.8000 | 7,863.4000 | 8,497.1000 | ||||||
| Depreciation (total) | - | - | - | - | - | ||||||
| Operating Result | 1,330.7410 | 2,079.5910 | 2,534.4000 | 2,209.8000 | 3,576.6000 | ||||||
| Interest Income | -7.1950 | -25.1190 | -28.2000 | -30.2000 | -56.9000 | ||||||
| Income Before Taxes | 1,329.8150 | 2,078.5110 | 2,553.5000 | 2,429.1000 | 3,810.4000 | ||||||
| Income Taxes | -434.2930 | -880 | -109.1000 | -313.3000 | 297.2000 | ||||||
| Minority Interests Profit | - | - | - | - | - | ||||||
| Net Income | 895.5220 | 1,198.5110 | 2,444.4000 | 2,115.8000 | 3,513.2000 | ||||||
Per Share
Cash Flow
| 2016 US GAAP in mill. USD |
2017 US GAAP in mill. USD |
2018 US GAAP in mill. USD |
2019 US GAAP in mill. USD |
2020 US GAAP in mill. USD |
|||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash Flow from Operating Activities | 1,473.3960 | 1,307.1120 | 2,195.1000 | 2,430 | 2,618.1000 | ||||||
| Cash Flow from Investing Activities | -1,046.9040 | -1,005.1820 | -1,463 | -2,027.8000 | -70.6000 | ||||||
| Cash Flow from Financing | -700.3910 | -24.4000 | -77.1000 | -252.1000 | -1,970.5000 | ||||||
| Decrease / Increase in Cash | -273.8990 | 277.5300 | 655 | 150.1000 | 577 | ||||||
| Employees | 5,400 | 6,200 | 7,400 | 8,100 | 9,123 | ||||||
